Alterity Therapeutics Files 6-K, Presents MSA Data
Ticker: PRNAF · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Nov 12, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-update, symposium, regulatory-filing
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K with symposium presentation on MSA progression tracking.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on November 12, 2024, to report its activities for November 2024. The filing includes an exhibit (99.1) detailing an ATH Presentation on Tracking MSA Progression at an International Symposium. This report is being incorporated by reference into several of Alterity's existing Registration Statements on Forms S-8 and F-3.
Why It Matters
This filing provides an update on Alterity's progress in tracking Multiple System Atrophy (MSA) progression, which is crucial for understanding the disease and developing potential treatments.
Risk Assessment
Risk Level: medium — The filing is a routine report and doesn't contain specific financial updates or material events, but it relates to a clinical-stage biotechnology company, which inherently carries higher risk.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH (company) — Abbreviation for Alterity Therapeutics
- Multiple System Atrophy (MSA) (medical_condition) — Disease progression being tracked
- Form S-8 (document) — Registration statement incorporated by reference
- Form F-3 (document) — Registration statement incorporated by reference
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report on the activities of Alterity Therapeutics Limited for the month of November 2024, specifically including an update on tracking MSA progression presented at an international symposium.
Which specific presentation is included as an exhibit in this filing?
Exhibit 99.1 is an 'ATH Presentation Tracking MSA Progression at Intl Symposium'.
Into which existing filings is this Form 6-K being incorporated by reference?
This Form 6-K is being incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the principal executive office address for Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Alterity Therapeutics indicates it files annual reports under Form 20-F.
Filing Stats: 192 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-11-12 06:27:54
Filing Documents
- ea0220786-6k_alterity.htm (6-K) — 14KB
- ea022078601ex99-1_alterity.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-096151.txt ( ) — 42KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 ATH Presentation Tracking MSA Progression at Intl Symposium 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: November 12, 2024 2